Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 10, 2009

View Archived Issues

Detailed results of CORD I study of Xiaflex in Dupuytren's contracture released

AP-1 and NF-kappaB inhibitors in early development at Bristol-Myers Squibb

Hovione's TwinCaps inhaler succesful in phase III influenza trial of CS-8958

Galenica acquires Om Pharma

Amarillo Biosciences provides update on phase II interferon alpha trial in influenza and colds

Cell Biosciences to acquire Alpha Innotech

AmorePacific describes TRPV1 antagonists for the treatment of pain

Osiris Therapeutics presents preliminary results for phase III Prochymal trials

S*Bio discloses PI3K and mTOR inhibitors as oncolytics

PDE4 inhibitors and mAChRs antagonists disclosed by GSK for respiratory diseases

Bristol-Myers Squibb presents SERT inhibitors and NK1 antagonists as anxiolytics

Medivation Technologies presents novel compounds for cognitive and psychotic disorders

Phase I/II study to determine safety/efficacy of KP-413 in atopic dermatitis

West Nile virus antibody MGAWN1 to be evaluated in phase II trial

Vivus reports results from two phase III Qnexa studies

M.D. Anderson Cancer Center and Arno Therapeutics to assess DB-67 in MDS in phase II trial

Brivanib alaninate is active as first- and second-line treatment in HCC patients

Prospective study shows tendency of menatetrenone to suppress postoperative HCC recurrence

ABT-869 exhibits promising clinical activity in Child-Pugh Type A HCC patients in phase II trial

ISTA presents preliminary results for T-Pred studies

FDA approves Bepreve for the treatment of ocular itching due to allergies

Salix receives FDA marketing approval for Metozolv ODT

Aeolus commences study of AEOL-10150 as a countermeasure to radiation

Aclidinium bromide improves pulmonary function in phase III trials; MAA filing planned for 2010

ChemGenex submits NDA to FDA for Omapro

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...